CTOs on the Move

Aledade

www.aledade.com

 
Aledade is a new company with an old-fashioned goal: putting doctors back in control of health care. Aledade partners with independent, primary care physicians to provide everything the doctors need to create and run an Accountable Care Organization (ACO) – from business and practice transformation services to upfront capital and a cutting-edge technology platform. Our customized solutions – and our continuous, on-the-ground support of our physician partners – will help doctors in all types of communities across America preserve their autonomy, deliver better care to their patients, reduce overall costs, and keep independent physician practices flourishing.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aledade.com
  • 4550 Montgomery Ave Suite 950
    Bethesda, MD USA 20814
  • Phone: 202.803.7979

Executives

Name Title Contact Details
Ritwik Tewari
 Chief Technology Officer Profile
Tyson Kopczynski
 Chief Information Security Officer Profile
Kallie Smith
 Director Information Security Profile
Eric Banks
 Chief Information Security Officer Profile

Funding

Aledade raised $30M on 06/15/2015
Aledade raised $20M on 01/11/2017
Aledade raised $23M on 12/19/2017
Aledade raised $46.1M on 10/17/2018
Aledade raised $10M on 01/19/2019
Aledade raised $64M on 04/20/2020
Aledade raised $100M on 01/19/2021
Aledade raised $123M on 06/06/2022

Similar Companies

Westbridge Agricultural Products

Through safe agricultural, home and garden products and technologies, Westbridge is cultivating environmental awareness.

ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​

Aspen Neuroscience

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Bellerophon Therapeutics

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.